The package will provide additional support for late-stage development and licensure of pre-pandemic mRNA-based vaccines, the ...
The main reason for this week's decline is that Moderna lowered its 2025 full-year revenue guidance, and by a wide margin.
The company's newer product, an RSV ( respiratory syncytial virus) vaccine, has also underperformed, contributing "minimal ...
Cases of norovirus infections are surging, but coming up with a way to prevent them has proven to be a challenge.
At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $1.5 billion to $2.5 billion -- down from ...
Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...
Shares of Moderna tumbled Monday after the vaccine maker predicted a steeper-than-expected sales drop in the new year.
Moderna's been anything but a high-flying growth stock in this investor's portfolio. So is it high time he gave up on this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback